Inhibikase Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
Revenue | $0 | $0 | $0 |
Gross Profit | -36 | -23 | |
EBITDA | -16,380 | -13,133 | -13,237 |
EBIT | -13,261 | ||
Net Income | -16,380 | -12,734 | -11,930 |
Net Change In Cash | 0 | 0 | 0 |
Free Cash Flow | -12,059 | -7,967 | -10,592 |
Cash | 49,573 | 139,220 | 38,269 |
Basic Shares | 172,306 | 94,180 | 90,050 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $260 | $123 |
Gross Profit | -60 | -26 | -13,357 | 116 |
EBITDA | -53,287 | -27,493 | -18,851 | -18,047 |
EBIT | -53,348 | -27,519 | -19,028 | -18,054 |
Net Income | -48,259 | -27,519 | -19,028 | -18,054 |
Net Change In Cash | 0 | 0 | 260 | 123 |
Free Cash Flow | -27,786 | -19,148 | -18,099 | -17,594 |
Cash | 139,220 | 56,490 | 9,165 | 7,188 |
Basic Shares | 98,310 | 23,712 | 5,333 | 4,201 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.11 |
2026-03-31 | -$0.09 |
2025-12-31 | -$0.09 |
2025-09-30 | -$0.13 |